Nicotinamide mononucleotide (NMN) supplementation, a product of the nicotinamide phosphoribosyltransferase (NAMPT), which acts as the rate limiting enzyme in the NAD+ biosynthesis, decreases the levels of inflammatory cytokines in mice fed on a high fat diet (HFD) and in a mouse model of aged-induced type 2 diabetes. Here, NAMPT is linked to type 2 diabetes mellitus.